Pipeline

Our lead self-amplifying vRNA immunotherapy program, ONCR-021, encodes an optimized genome of the coxsackievirus A21 (CVA21). We selected to advance ONCR-021 based on a number of CVA21’s properties, including:

• Demonstrated safety and tolerability of virions after intravenous (IV) administration in patients
• Ability of the genome to replicate in solid tumors, including lung tumors
• Inability to insert into host chromosome, eliminating the potential of insertional mutagenesis

Learn more about our selectively self-amplifying RNA Platform, including our novel lipid nanoparticle (LNP) delivery strategy designed to overcome the challenges caused by neutralizing antibodies that have likely limited the efficacy of prior efforts to treat tumors utilizing IV administration of CVA21.

Development Status

In preclinical models, we have demonstrated proof of concept that ONCR-021 when administered intravenously, is able to successfully deliver a selectively self-amplifying RNA immunotherapy to tumors, leading to production of replication-competent virions within tumors that causes tumor growth inhibition.

We plan to file an investigational new drug (IND) application for ONCR-021 with the U.S. Food and Drug Administration in mid-2023.

ONCR-788, our second selectively self-amplifying RNA immunotherapy product candidate, encodes a modified genome of the Seneca Valley Virus (SVV).

Learn more about our selectively self-amplifying RNA Platform.

Development Status

In preclinical models, we have demonstrated proof of concept that ONCR-788, when administered intravenously, is able to successfully deliver a selectively self-amplifying RNA-immunotherapy to tumors, leading to production of replication-competent virions within tumors that stimulates the immune system and causes tumor growth inhibition.

Preclinical studies have been conducted and a development candidate has been announced. Oncorus is seeking partnership or additional funding for this program.

We are pursuing a viral immunotherapy, ONCR-719, to specifically target brain cancer, including glioblastoma multiforme (GBM). ONCR-719 is a novel, armed oncolytic HSV-1 vector engineered with targeted entry via EGFR/EGFRvIII and expresses four immunomodulatory payloads to reverse GBM’s immunosuppressive tumor microenvironment. In addition, ONCR-719 is derived from a potent HSV-1 isolate to drive oncolysis, is engineered with fusogenic mutations to enhance viral spread, and uses Oncorus’ clinically validated microRNA attenuation strategy to inhibit viral replication in healthy cells.

Development Status

Development candidate ONCR-719 has been nominated and is available for partnering. Oncorus is seeking partnership or non-dilutive funding for this program.